Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT07741565 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

HNSCC
SCC - Squamous Cell Carcinoma
Oral Cancer

Interventions

DRUG: Nivolumab-IRDye800

Sponsor

Vanderbilt-Ingram Cancer Center